DDInter1033 DDInter1840
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
PTK2B {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
PTK2B {u} (Gene) covaries with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Leflunomide (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Leflunomide (Compound) binds PTK2B (Gene) and PTK2B (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Leflunomide (Compound) binds PTK2B (Gene) and PTK2B (Gene) covaries with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)